CTOs on the Move

Alnara Pharmaceuticals

www.alnara.com

 
Alnara Pharmaceuticals, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alnara.com
  • 840 Memorial Dr
    Cambridge, MA USA 02139
  • Phone: 617.349.3690

Executives

Name Title Contact Details

Similar Companies

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Aspen Laser

Aspen Laser Systems is redefining pain management and recovery with our high intensity, class IV laser therapy devices. With over 30 years of experience, Aspen Laser delivers quality products and long-lasting results for your patients.

HospiScript Services

HospiScript Services, LLC is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elligo Health Research

Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.